BioAdaptives, Inc. develops and markets nutraceutical and wellness products for cognitive performance, brain recovery, pet vitality and weight management. Company news centers on the MyndSystem platform, including MyndMed for daytime cognitive support and MyndRenew for nighttime recovery support, as well as NeuroRush, PawPa Regen dog chews and Zeranovia.
Recurring updates cover product launches, direct-to-consumer availability, formulation positioning, pilot and dosage testing, athlete-safety testing for MyndMed, and expansion of pet-wellness and nootropic product lines.
BioAdaptives (OTC: BDPT) addresses an inadvertent early release of shareholder information regarding an upcoming reverse stock split. The company explains that since January 2020, outstanding shares increased by 6,530% from 18.5 million to 1.23 billion as of June 2024, without corresponding revenue growth. New management, led by CEO James Keener, plans to implement the reverse split alongside a business transformation strategy that includes launching several new products, establishing new distribution channels, and improving marketing efforts with enhanced packaging.
BioAdaptives (OTC: BDPT) announces the appointment of Gimhana Dissanayake to its Board of Directors. Dissanayake, currently the VP of Operational Sales for North America at Hertz (NYSE: HTZ), brings over 20 years of experience in strategic growth and operational excellence. He has been key in enhancing the market presence of Hertz, Dollar, and Thrifty brands and has formed significant partnerships with Fortune 500 companies. His academic background includes degrees from Oklahoma State University, California State University, Sacramento, and executive education from Cornell and Wharton. The appointment is expected to bolster BioAdaptives' growth and innovation in the wellness sector.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.